Get the Stockscreener App
3.34
2.77%
0.09
After Hours:
3.34
4 D Molecular Therapeutics Inc Stock (FDMT) Forecast
The 4 D Molecular Therapeutics Inc (FDMT) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $9.4172, representing a +181.95% increase from the current price of $3.34. The highest analyst price target is $11.09, and the lowest is $7.7478.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month FDMT Price Target
Average 5.7056
(+70.83% Upside)
Is 4 D Molecular Therapeutics Inc (FDMT) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 50.75 | Neutral |
| STOCH(9,6) | 79.26 | Neutral |
| STOCHRSI(14) | 93.37 | Sell |
| MACD(12,26) | -0.1347 | Buy |
| ADX(14) | 21.16 | Neutral |
| William %R | -26.58 | Neutral |
| CCI(14) | 54.20 | Neutral |
Buy: 1
Sell: 1
Neutral: 5
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
3.097
Buy
|
3.1703
Buy
|
| MA20 |
3.0133
Buy
|
3.2036
Buy
|
| MA50 |
3.7399
Sell
|
3.7834
Sell
|
| MA100 |
4.7937
Sell
|
5.2791
Sell
|
| MA200 |
8.8614
Sell
|
9.2994
Sell
|
Buy: 4
Sell: 6
Neutral: 0
Summary: Sell
According to our latest analysis, FDMT could be considered a Moderate Sell, with 17 technical analysis indicators signaling 5 Buy signals, 7 signaling Sell signals and 5 Neutral signals. This might not be a good time to consider opening new positions on FDMT, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 50.75 indicates that FDMT is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 79.26 indicates that FDMT is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 93.37 indicates that FDMT is oversold. This suggests that FDMT price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 21.16 suggests that there may be some movement in price, but it lacks strength or conviction.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 54.2 indicates that FDMT is still overbought but not to an extreme extent.
Long-term FDMT price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about 4 D Molecular Therapeutics Inc financial reports and earnings history, 4 D Molecular Therapeutics Inc (FDMT) stock could reach $15.44 by 2030, $42.35 by 2040 and $56.00 by 2050. See the projected annual prices until 2050 of the 4 D Molecular Therapeutics Inc stock below:
- 4 D Molecular Therapeutics Inc (FDMT) is expected to reach an average price of $18.08 in 2035, with a high prediction of $16.97 and a low estimate of $14.75. This indicates an $441.41% rise from the last recorded price of $3.34.
- 4 D Molecular Therapeutics Inc (FDMT) stock is projected to chart a bullish course in 2040, with an average price target of $43.52, representing an $1,203% surge from its current level. The forecast ranges from a conservative $43.73 to a sky-high $42.35.
- Our analysts predict 4 D Molecular Therapeutics Inc (FDMT) to jump 1,917% by 2045, soaring from $66.93 to an average price of $67.38, potentially reaching $67.34. While $66.93 is the low estimate, the potential upside is significant.
- 4 D Molecular Therapeutics Inc (FDMT) stock is expected to climb by 2050, reaching an average of $56.28, a $1,585% jump from its current level. However, a wide range of estimates exists, with high and low targets of $56.00 and $54.99, respectively, highlighting the market's uncertainty.
4 D Molecular Therapeutics Inc Stock (FDMT) Year by Year Forecast
4 D Molecular Therapeutics Inc Stock (FDMT) Price Forecast for 2025
4 D Molecular Therapeutics Inc Stock (FDMT) is expected to reach an average price of $11.36 in 2025, with a high prediction of $22.65 and a low estimate of $0.0673. This indicates an +240.04% rise from the last recorded price of $3.34.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| May, 2025 | $8.7865 | $7.7478 | $11.09 | +163.07% |
| June, 2025 | $5.7239 | $5.4534 | $11.34 | +71.37% |
| July, 2025 | $3.4381 | $0.4044 | $6.0117 | +2.94% |
| August, 2025 | $0.9055 | $0.1687 | $6.515 | -72.89% |
| September, 2025 | $2.4429 | $0.0673 | $4.016 | -26.86% |
| October, 2025 | $0.4029 | $0.3503 | $4.1597 | -87.94% |
| November, 2025 | $4.6355 | $1.316 | $3.4755 | +38.79% |
| December, 2025 | $5.8213 | $4.9718 | $5.7813 | +74.29% |
4 D Molecular Therapeutics Inc Stock (FDMT) Price Forecast for 2026
The predicted value for 4 D Molecular Therapeutics Inc (FDMT) in 2026 is set at an average of $7.677. Estimates vary from a peak of $14.98 to a trough of $0.3699, indicating an +129.85% surge from the present price of $3.34.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $3.7039 | $5.4107 | $5.0207 | +10.90% |
| February, 2026 | $0.6165 | $2.8102 | $1.9902 | -81.54% |
| March, 2026 | $4.1291 | $3.6428 | $3.4491 | +23.63% |
| April, 2026 | $3.8149 | $3.3986 | $3.3823 | +14.22% |
| May, 2026 | $2.8675 | $4.7481 | $4.3312 | -14.15% |
| June, 2026 | $10.35 | $0.3699 | $12.49 | +209.88% |
| July, 2026 | $11.80 | $8.4267 | $14.98 | +253.42% |
| August, 2026 | $10.63 | $7.2915 | $11.99 | +218.31% |
| September, 2026 | $8.9757 | $7.9402 | $12.52 | +168.73% |
| October, 2026 | $7.7781 | $6.0631 | $10.58 | +132.88% |
| November, 2026 | $6.1405 | $3.5399 | $8.0768 | +83.85% |
| December, 2026 | $6.0247 | $2.3178 | $12.06 | +80.38% |
4 D Molecular Therapeutics Inc Stock (FDMT) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for 4 D Molecular Therapeutics Inc (FDMT) is $13.06, with a high forecast of $25.93 and a low forecast of $0.1832. This indicates an +290.96% increase from the last price of $3.34.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $7.5521 | $5.0415 | $8.5521 | +126.11% |
| February, 2027 | $7.4995 | $6.9789 | $13.37 | +124.53% |
| March, 2027 | $7.7737 | $6.9363 | $9.85 | +132.75% |
| April, 2027 | $5.5811 | $4.8934 | $8.3005 | +67.10% |
| May, 2027 | $5.3185 | $4.9035 | $6.8579 | +59.24% |
| June, 2027 | $0.2427 | $0.1973 | $6.1253 | -92.73% |
| July, 2027 | $1.4901 | $0.1832 | $1.8151 | -55.39% |
| August, 2027 | $2.7174 | $0.1938 | $3.0774 | -18.64% |
| September, 2027 | $10.39 | $2.5243 | $11.65 | +211.13% |
| October, 2027 | $7.7391 | $6.8522 | $11.71 | +131.71% |
| November, 2027 | $17.61 | $7.0577 | $25.93 | +427.14% |
| December, 2027 | $21.99 | $16.37 | $22.85 | +558.40% |
4 D Molecular Therapeutics Inc Stock (FDMT) Price Forecast for 2028
In 2028, 4 D Molecular Therapeutics Inc (FDMT) is projected to reach an average price of $13.90, with a high projection of $26.78 and a low estimate of $1.0113. This indicates an +316.10% rise from the last price of $3.34.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $16.94 | $16.27 | $26.78 | +407.13% |
| February, 2028 | $16.22 | $13.39 | $19.04 | +385.58% |
| March, 2028 | $18.39 | $5.8774 | $21.97 | +450.74% |
| April, 2028 | $14.27 | $11.41 | $26.25 | +327.23% |
| May, 2028 | $9.558 | $6.728 | $26.33 | +186.17% |
| June, 2028 | $4.8728 | $4.6728 | $15.60 | +45.89% |
| July, 2028 | $1.6125 | $2.2764 | $11.70 | -51.72% |
| August, 2028 | $3.104 | $1.8064 | $3.016 | -7.07% |
| September, 2028 | $3.1093 | $4.128 | $3.183 | -6.91% |
| October, 2028 | $0.3445 | $2.5145 | $2.4256 | -89.69% |
| November, 2028 | $5.034 | $1.4166 | $6.653 | +50.72% |
| December, 2028 | $0.1287 | $1.0113 | $9.155 | -96.15% |
4 D Molecular Therapeutics Inc Stock (FDMT) Price Forecast for 2029
The 2029 price forecast for 4 D Molecular Therapeutics Inc Stock (FDMT) is $9.167 on average, with a high prediction of $18.09 and a low estimate of $0.2415. This represents an +174.46% increase from the previous price of $3.34.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $2.6628 | $0.2415 | $7.3372 | -20.27% |
| February, 2029 | $4.3981 | $2.6054 | $2.7081 | +31.68% |
| March, 2029 | $6.5033 | $4.1707 | $3.3344 | +94.71% |
| April, 2029 | $9.0285 | $5.2159 | $6.9975 | +170.32% |
| May, 2029 | $10.78 | $10.87 | $10.60 | +222.76% |
| June, 2029 | $12.38 | $11.81 | $11.50 | +270.52% |
| July, 2029 | $10.20 | $10.24 | $9.6716 | +205.41% |
| August, 2029 | $13.14 | $10.30 | $12.34 | +293.48% |
| September, 2029 | $17.20 | $14.91 | $16.52 | +414.89% |
| October, 2029 | $17.52 | $17.36 | $18.09 | +424.52% |
| November, 2029 | $14.27 | $16.69 | $17.25 | +327.37% |
| December, 2029 | $14.60 | $14.96 | $13.07 | +337.11% |
4 D Molecular Therapeutics Inc Stock (FDMT) Price Forecast for 2030
4 D Molecular Therapeutics Inc Stock (FDMT) is expected to reach an average price of $8.3277 in 2030, with a high forecast of $16.13 and a low forecast of $0.5229. This signifies an +149.33% surge from the last price of $3.34.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $14.81 | $15.69 | $15.44 | +343.44% |
| February, 2030 | $16.54 | $15.31 | $15.40 | +395.09% |
| March, 2030 | $14.78 | $14.94 | $16.13 | +342.56% |
| April, 2030 | $0.3466 | $3.1866 | $13.65 | -89.62% |
| May, 2030 | $1.3681 | $0.5229 | $3.4782 | -59.04% |
| June, 2030 | $2.4334 | $2.5407 | $0.5916 | -27.14% |
| July, 2030 | $1.4649 | $1.7549 | $1.4249 | -56.14% |
| August, 2030 | $6.8101 | $3.5975 | $3.3801 | +103.90% |
| September, 2030 | $5.9254 | $6.0891 | $4.2028 | +77.41% |
| October, 2030 | $3.8669 | $5.8469 | $4.5417 | +15.78% |
| November, 2030 | $3.2022 | $3.8022 | $2.8122 | -4.13% |
| December, 2030 | $3.2774 | $1.3548 | $2.6452 | -1.87% |
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):